Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Other Non Operating Income (2016 - 2025)

Standard Biotools (LAB) has disclosed Other Non Operating Income for 16 consecutive years, with -$2.1 million as the latest value for Q3 2025.

  • Quarterly Other Non Operating Income changed N/A to -$2.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, up 135.54% year-over-year, with the annual reading at -$5.0 million for FY2024, 460.03% down from the prior year.
  • Other Non Operating Income for Q3 2025 was -$2.1 million at Standard Biotools, down from $3.9 million in the prior quarter.
  • The five-year high for Other Non Operating Income was $25.2 million in Q1 2024, with the low at -$30.2 million in Q4 2024.
  • Average Other Non Operating Income over 5 years is $71.43, with a median of $217000.0 recorded in 2021.
  • Peak annual rise in Other Non Operating Income hit 2131.24% in 2024, while the deepest fall reached 2849.86% in 2024.
  • Over 5 years, Other Non Operating Income stood at $315000.0 in 2021, then plummeted by 62.22% to $119000.0 in 2022, then surged by 823.53% to $1.1 million in 2023, then tumbled by 2849.86% to -$30.2 million in 2024, then skyrocketed by 93.08% to -$2.1 million in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$2.1 million, $3.9 million, and -$30.2 million for Q3 2025, Q1 2025, and Q4 2024 respectively.